exRNAdisease

Entry Detail

---



General Information

Database ID: exR0089366 RNA Name: hsa-miR-93-5p RNA Type: miRNA Chromosome: chr7 Starnd: - Coordinate: Start Site(bp): 100093815 End Site(bp): 100093837 External Links: hsa-miR-93-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand AFF4 chr5 132875395 132963634 - ADARB1 chr21 45073853 45226560 + LONP2 chr16 48244300 48363122 + ZNF468 chr19 52838010 52857649 - CAPRIN1 chr11 34051731 34102610 + C9orf40 chr9 74946583 74952912 - WAC chr10 28532493 28623112 + MAP3K3 chr17 63622415 63696303 + SEC16A chr9 136440096 136483759 - WASF3 chr13 26557683 26688948 + NUDT21 chr16 56429133 56452199 - NAA16 chr13 41311267 41377030 + DYNLRB1 chr20 34516409 34540958 + OCRL chrX 129539849 129592561 + CLIP4 chr2 29097705 29189643 + SLAIN2 chr4 48341529 48426201 + SLC46A3 chr13 28700064 28718970 - CHD2 chr15 92900189 93027996 + MTHFR chr1 11785723 11806455 - ZDHHC12 chr9 128720870 128724127 - KLHL28 chr14 44924319 45042322 - EFNA3 chr1 155078837 155087538 + LDLRAD3 chr11 35943981 36232136 + WIPF2 chr17 40219304 40284136 + PXYLP1 chr3 141228726 141367753 + FCF1 chr14 74713144 74738620 + EAPP chr14 34515938 34539711 - PDRG1 chr20 31944337 31952046 - CHD9 chr16 53055033 53329150 + CUL1 chr7 148697914 148801110 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001495 chr5 68470703 68471364 + hsa_circ_0000494 chr13 76134888 76143643 + hsa_circ_0000018 chr1 15860731 15863309 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC015871.3 chr15 79920195 79922455 - AC021078.1 chr5 149494314 149504670 - AC021092.1 chr19 44103007 44113183 - AC024940.6 chr12 31280422 31280895 - AC084082.1 chr8 66112667 66126632 + AC087477.2 chr15 96354237 96405235 + AC243964.3 chr19 44631573 44725217 - AL031428.1 chr1 23020147 23088058 - AL137782.1 chr13 75549773 75807120 + AL158206.1 chr9 19453209 19455173 + AL161772.1 chr13 20699307 20703718 - ARHGAP27P1-BPTFP1-KPNA2P3 chr17 64749663 64781707 - CKMT2-AS1 chr5 81201341 81301565 - EPB41L4A-AS1 chr5 112160526 112164818 + ERICD chr8 140636281 140638283 + FGD5-AS1 chr3 14920347 14948424 - H19 chr11 1995176 2001470 - HAGLR chr2 176164051 176188958 - HOTAIR chr12 53962308 53974956 - MALAT1 chr11 65497688 65506516 + NEAT1 chr11 65422774 65445540 + NORAD chr20 36045618 36051018 - SNHG16 chr17 76557764 76565348 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.